Previous attempts to profile baseline recycling activities were unsuccessful due to the wide variety of measurement units, reporting practices, and differentiation of the mass recycled.
To address the growing challenge of plastic waste in biopharma manufacturing, this project proposes a two-phase, US-based initiative aimed at enabling circularity for single-use plastics. The solution will:
Waste stream clarity- detailed profile of plastic waste types and disposal methods
Technology Identification- evaluating viable recycling technologies tailored to biopharama waste profiles
By implementing process improvements identified in this project—such as standardized waste stream profiling and evaluation of advanced recycling technologies—an organization could reduce disposal costs associated with incineration, landfill, and downcycling by up to 40%, enabling a circular economy for high-value plastics and strengthening sustainability commitments across the biopharmaceutical industry.
Intermediate Report with Survey Results (Completed)
Final Report with summary of the survey results, highlighting the options and providing recommendations (In Progress)
McClure, M., Presenter, Integrated Continuous Biomanufacturing Conference, Leesburg, Virginia, October 20, 2024.
Barbaroux, M., Presenter, Defining an ideal future for circularity of single-use plastics, NIIMBL National Meeting, Washington, DC, June 24, 2025.
Connell-Crowley, L., Presenter, Defining an Ideal Future for Plastics, Integrated Continuous Biomanufacturing Conference, Leesburg, Virginia, October 20, 2024.
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.

Cytiva
Amgen Inc.
AstraZeneca
Genentech, Inc.
GlaxoSmithKline, LLC
Sartorius Stedim